↓ Calculate your dosage
Dr. Ashley Froese, DO sat in the room for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. The committee recommended KPV for the 503A bulks list. That is not FDA approval, and it is not a finding that KPV works in people. Watch on YouTube →
Dr. Andrew Jones, DVM (Veterinary Secrets) walks BPC-157, TB-500, and KPV for dogs and cats. On KPV he talks about allergies, atopy, and gut inflammation as a driver of itching and scratching. He also says these peptides are not broadly FDA-approved for veterinary use and the research is thinner than people want. That is a veterinarian thinking out loud, not a canine trial. Watch on YouTube →
0
Placebo-controlled RCTs of native KPV
No indexed trial of Lys-Pro-Val itself as a finished human drug. Bounded claim: none found in PubMed or ClinicalTrials.gov this session.
20
Women in the CZEN-002 analog gel study
Open-label, no placebo arm, 2004 company report. Related octapeptide — not the KPV vial sold online.
nM
Cell concentrations that quieted NF-κB
Dalmasso 2008: nanomolar KPV blocked NF-κB and MAPK in gut and immune cells via PepT1.
8–6
PCAC vote July 23, 2026
One abstention. Advisory only. FDA staff had recommended against listing. No final compounding rule as of this review.
KPV is three amino acids — lysine, proline, valine — clipped from the tail of alpha-melanocyte-stimulating hormone. α-MSH is a pigmentation hormone. KPV keeps much of the anti-inflammatory job and drops most of the tanning job. That is why clinics talk about it for gut lining and angry skin instead of for a tan.
The fragment
α-MSH 11–13
The C-terminal tripeptide of a 13-amino-acid hormone your pituitary already makes. Small enough to ride the gut peptide transporter PepT1.
How it gets in
PepT1
PepT1 sits in small-intestine lining and shows up in inflamed colon. Dalmasso showed KPV uses that door. Knock the transporter out in mice and the cancer-prevention signal vanished.
Inside the cell
NF-κB ↓
Once inside, KPV turns down NF-κB and MAPK — the same inflammatory switches steroids hit, without being a steroid. Some of that still worked in mice whose melanocortin-1 receptor was broken.
What it is not
Not a drug
Not FDA-approved. Not a proven treatment for Crohn’s, eczema, rosacea, or a dog’s hot spot. Research vials are not sterile medicine. This page is for a person deciding, not a prescription.
The stack is lopsided on purpose. Mouse colitis is real. A human drug trial of native KPV is not. Do not read “lots of papers” as “lots of patients.”
Animal + cell papers
Named KPV / α-MSH(11–13) colitis, skin, and mechanism studies — not every PubMed hit for the letters KPV
Human signal
CZEN-002 gel, n=20, open-label, related analog; plus ex-vivo human skin iontophoresis — not a patient RCT
Native-KPV RCTs
None found indexed in PubMed or listed as a completed native-KPV drug trial on ClinicalTrials.gov this session
DSS + TNBS colitis
Oral, in water
Dalmasso put KPV in drinking water. Mice with two standard colitis models lost less of the inflammatory cytokine spike (IL-1β, IL-6, TNF, IFN-γ) and looked better on histology. Nanomolar on cells; oral on mice.
Transfer colitis + MC1R-mutant mice
Rescued
Kannengiesser used DSS and T-cell transfer colitis. KPV sped weight regain and cut myeloperoxidase. In mice with a broken melanocortin-1 receptor — a setup that otherwise killed the DSS group — KPV treatment saved the treated animals.
Colitis-associated tumors
PepT1-dependent
Viennois showed PepT1 overexpression made AOM/DSS tumors worse, knockout made them better, and KPV blocked tumorigenesis in normal mice — but not in PepT1-knockout mice. Human colorectal tumor biopsies also ran high PepT1. That is a mouse cancer model plus human tissue staining, not a cancer treatment trial.
Skin inflammation models
Itch / barrier
α-MSH-family peptides, including KPV, reduce contact-hypersensitivity swelling in mice. A 2025 keratinocyte paper found KPV lowered fine-dust-driven apoptosis and MAPK/NF-κB in skin cells. A 2019 wound-healing review asks whether melanocortin peptides belong in cutaneous repair — it does not answer with a human RCT.
If a row is not native KPV in a living patient, the table says so. Analog data is real. It is not a substitute for a KPV trial.
| # |
What was tested |
Type |
n |
Outcome |
| 1 |
CZEN-002 vaginal gel — synthetic octapeptide (CKPV)₂ derived from α-MSH / KPV, not native Lys-Pro-Val. Zengen open-label Phase I/II, vulvovaginal candidiasis, 2004 company report. EurekAlert · DrugBank DB05479 |
Open-label analog |
20 enrolled / 17 completed |
Analog, no placebo Company reported ~88% KOH / culture clearance, no severe adverse events, plasma levels mostly undetectable. Never became an approved drug. Development status unknown. |
| 2 |
Iontophoresis across microporated human skin — lab skin, not a clinic visit. Pawar et al., Journal of Pharmaceutical Sciences 2017. PMID 28343991 |
Ex-vivo human skin |
Skin samples |
Delivery math Native KPV can be pushed through prepared human skin with current. This measures transport, not itch scores or IBD remission. |
| 3 |
Native KPV capsules / injections / creams in people |
RCT |
— |
None found Bounded: none indexed in PubMed and no completed native-KPV interventional trial turned up on ClinicalTrials.gov this session. That is a funding and regulatory fact, not proof it was tested and failed. |
Reality check. The mouse gut story is one of the cleaner peptide-preclinical files you will find. The human file for the exact tripeptide in the vial is still empty. Anyone selling “clinically proven KPV” is either talking about cells, mice, or a different analog.
People do not buy KPV because they love PepT1. They buy it for an angry gut or angry skin — including itchy, allergic, hotspot-type skin in dogs. That last use is common on veterinary blogs and DVM YouTube. Dr. Andrew Jones (DVM, Veterinary Secrets) puts KPV next to BPC-157 and TB-500 in the peptides-for-pets talk embedded above: allergies, atopy, autoimmune noise, and gut inflammation as a driver of itch. He also says the research is thinner than people want, and these peptides are not broadly FDA-approved for veterinary use. No canine RCT was found this session. That video is a veterinarian thinking out loud, not a trial.
Gut lining
Best-fit mechanism
Oral KPV is the use that matches the papers: PepT1 in inflamed intestine, drinking-water colitis models, cytokine drop. Human IBD still runs on mesalamine, steroids, and biologics with actual trial programs. KPV is the cheap unpatentable fragment those programs did not fund.
Human skin
Plausible, unproven
Contact-hypersensitivity mice, keratinocyte culture, and compounded creams. Atopic dermatitis and psoriasis still have FDA-approved drugs with outcome scores (EASI, PASI). KPV cream is a bet on mechanism plus anecdote.
Dogs — itch, allergies, hot spots
No trial dose
Itch in dogs is usually a cycle, not a peptide deficiency: atopy, fleas, food, ear or anal-gland pain, or a wound that got infected because the dog would not stop licking. A hot spot (acute moist dermatitis) is often surface bacteria plus self-trauma — clip, clean, stop the lick cycle, and often antibiotics or steroids. Jones’s KPV pitch is anti-inflammatory: oral for gut (he flags gut inflammation as a big driver of itching and scratching with allergies), a topical cream for a local patch, injectable for a more whole-body immune story. BPC-157 in that same talk is the gut/repair peptide; TB-500 is the more systemic tissue-healing one. None of that has a dog RCT. Apoquel, Cytopoint, steroids, and antibiotics for a wet hotspot remain the tools with outcome data. If a veterinarian is already in the conversation, KPV is adjunct-at-best, not a replacement — and gray-market pet peptides are not a sterile clinic product.
Research only
KPV 5 mg vial
$27–65
gray-market “research” lyophilized vial, 2026 vendor ranges
Often 10–25 days at 200–500 mcg/day
Research only
Typical month at 500 mcg/day
$45–170
depends on 5 mg vs 10 mg vial and whether you swallow or inject
No COA on a cheap vial is not a bargain
Most evidence
Standard IBD / eczema drugs
$10–$4k+
topical steroid on the low end; Dupixent / IBD biologics on the high end
These have human trials. KPV does not.
Vet standard
Dog allergy control
Rx
Apoquel, Cytopoint, steroids, antibiotics for infected hotspots — priced at the clinic, not a research site
Evidence-backed first; peptide blogs second
There is no FDA-approved KPV dose. The numbers below are what telehealth peptide pages and community write-ups repeat. They are not a prescription. Oral is the route that matches the colitis papers. Injection is what people use when they want systemic exposure. Topical is what people use on a patch of skin. Capsules do not need the reconstitution calculator — vials do.
Starter
200 mcg
Once daily, oral or subcutaneous, to check tolerance. Common floor of clinic write-ups.
Common band
250–500 mcg
Once daily, or 250 mcg twice daily oral for gut-focused protocols. Beverly Hills Rejuvenation Center lists 200–500 mcg SC/IM 1–2×/day as physician-directed compounding talk — still not an approved label.
clinic-reported
Upper reported
1,000 mcg
Some oral gut protocols stack to 1 mg/day. Least evidenced end of an already unevidenced human dose range.
Critical caveat
No label
Gray-market vials are not sterile medicine. “Research use only” is a liability phrase, not a purity guarantee. Do not add bacteriostatic water to a capsule, and do not add water to anything that is not lyophilized powder meant to be reconstituted.
FDA / PCAC
Not approved. Advisory yes vote.
KPV is not an approved drug. On July 23, 2026 PCAC recommended adding KPV (free base and acetate) to the 503A bulks list for wound healing and inflammatory conditions, 8 yes / 6 no / 1 abstain — the same split as BPC-157 that day, and against FDA staff’s “do not list” brief. McDermott and Buchanan Ingersoll both stress the vote does not let pharmacies start compounding. Rulemaking had not published as of this review.
WADA / USADA
Not named. S0 still exists.
KPV is not listed by name on the 2026 Prohibited List the way BPC-157 is. WADA S0 still bans pharmacological substances with no governmental approval for human use. Tested athletes should treat unnamed research peptides as a failed test waiting to happen and ask Global DRO, not a forum.
Follow the money
Three amino acids. No patent story.
A tripeptide this short is brutal to monopolize. Zengen tried a modified analog (CZEN-002) for yeast infection and did not finish the race. Nobody funds a $100 million ulcerative-colitis RCT on a molecule you can synthesize in a garage. “No large human trial” here is a business finding first. FDA staff still argued the human safety file was too thin to compound — that is the other pole, and it is also on the record.
What the papers show
Oral KPV reduced inflammatory cytokines in two mouse colitis models and needed PepT1 to matter in a colitis-cancer model (PMID 18061177, 27458604).
Anti-inflammatory effects showed up even when MC1R was broken (PMID 18092346) — so “it’s just a melanocortin agonist” is too small a sentence.
Skin story is cells, contact-hypersensitivity mice, and delivery through prepared human skin — not eczema RCTs (PMID 40073467, 28343991).
The only completed human clinical-looking dataset is a 20-person open-label analog gel for vaginal yeast, not IBD or dermatitis.
What named clinicians say on camera
Dr. Ashley Froese, DO (primary care; peptide education). She attended PCAC. Her recap: the committee recommended six of seven peptides including KPV; the vote is not approval; she trains clinicians for the patient wave anyway.
YouTube
Dr. Alex Tatem, MD (board-certified urologist). Dedicated KPV video: strong animal mechanism, NF-κB/MAPK, PepT1, and he says the quiet part — zero human clinical trials for the peptide people are buying.
YouTube
Dr. Andrew Jones, DVM (Veterinary Secrets; not the chiropractor of a similar name). Peptides-for-pets talk: BPC-157, TB-500, and KPV. On KPV he covers allergies / atopy, gut inflammation driving itch, plus oral vs cream vs injectable. He states these peptides are not broadly FDA-approved for vet use and the evidence is mostly preclinical. Credential is veterinary, not a canine RCT.
YouTube
No organ-toxicity file like high-dose niacin or iron overload. In the animal work, KPV is used at tiny (nanomolar-to-microgram) amounts. Clinic write-ups describe it as generally well tolerated. That is not the same thing as a human safety database. There is no labeled overdose ceiling because there is no label.
What people report
Mild GI upset on oral; injection-site irritation; the usual peptide-vial infection risk if sterile technique is sloppy. Mast-cell / histamine talk exists in community notes — not a trial AE table.
Who should be careful
Anyone with an active skin infection (especially a dog hotspot that is wet, crusted, or spreading). Pregnant or nursing people — no human reproductive data. Tested athletes (S0). Anyone stacking unverified research powders as if they were USP medicine.
The analog footnote
CZEN-002’s 20-person gel study reported no severe adverse events and almost no systemic absorption. That is a different molecule, a different route, and a company press release.
The bottom line — in plain English
What it is. KPV is a three-amino-acid tail of the tanning hormone α-MSH. In cells and mice it calms the NF-κB inflammatory switch, especially in gut lining that has opened the PepT1 door.
Who’s using it. Peptide clinics and research-chemical buyers for gut inflammation and skin. Some integrative veterinarians discuss it for allergic or itchy dogs — Jones’s saved Peptides-playlist talk is the clearest DVM version of that pitch, including the gut-itch idea. None of those uses has a native-KPV randomized trial behind it.
What the law says. Not FDA-approved. PCAC recommended it for the compounding bulks list on July 23, 2026 (8–6–1). FDA has not finished rulemaking. WADA does not name it; S0 still catches unapproved pharmacology.
What the research shows. Mouse colitis: real, replicated, mechanistic. Human native KPV: we found none indexed. The closest human clinical-looking dataset is a 2004 open-label analog gel in 20 women for yeast infection that never became a product.
- If you want the use that matches the papers, it is oral KPV aimed at an inflamed gut — and even that is still a mouse-to-human leap.
- If the problem is a dog’s hot spot, see a veterinarian first. Infection and self-trauma are not a peptide deficiency.
- A PCAC yes vote is a political-scientific event, not a gold-standard trial and not a license to compound tomorrow.
- Cheap plus unpatentable is why the trial is missing. That is not the same sentence as “it was tested and failed.”
- Gray-market vials have no FDA sterility or potency oversight. The calculator below is reconstitution math, not a medical order.
Follow the money
A patented IBD biologic can be billed in the thousands per month and supports Phase 3. Lys-Pro-Val can be made for dollars and supports blog posts. Zengen tried to productize a KPV-related analog twenty years ago and the trail goes cold after a 20-person open-label gel study. FDA staff told PCAC the human file was too thin. The committee voted to recommend compounding anyway. Those are not contradictions if you separate “does a mouse study exist?” from “will a company pay for a human one?” You decide which gap matters for your body, or your animal’s, with a clinician in the loop.